secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2022-11-29T23:59:59+00:00
Accession:  0001193125-22-293893
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum discontinues OHANA Phase 2b trial of volixibat in ICP due to enrollment feasibility
--------------------------------------------------------------------------------

- Discontinued Phase 2b OHANA trial of volixibat for intrahepatic cholestasis of pregnancy (ICP).
- Interim analysis showed meaningful reductions in serum bile acids and pruritus in treated patients.
- Decision driven by unique enrollment challenges in high-risk pregnancy setting.
- Company will prioritize other pipeline programs following the discontinuation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312522293893/0001193125-22-293893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312522293893/d426142d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-293893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer